Cat. #153996
RAP as an LRP1 antagonist
Cat. #: 153996
Sub-type: Inhibitor
Availability: Please enquire for quantities and pricing
Target: LRP1
Purpose: Inhibit LRP1 function
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Dudley K. Strickland
Institute: University of Maryland
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: RAP as an LRP1 antagonist
- Alternate name: receptor-associated protein
- Research fields: Cell signaling and signal transduction;Disease (not cancer);Metabolism;Other
- Tool type ecom: Protein
- Tool sub type: Inhibitor
- Disease: Alzheimer's;Alzheimer's disease
- Target: LRP1
- Description: Receptor-Associated Protein (RAP) is a chaperone of LRP1 (lipoprotein receptor-related protein 1). Usually, at low pHs the D3 domain unfolds and RAP dissociates from LRP1. In contrast, this RAP was engineered by Prasad et al. 2015, to overcome this. A disulfide bond was introduced to RAP, resulting in a stable RAP, which allows high affinity binding to LRP1. As a result, this RAP is an effective inhibitor of LRP1 activity. This stable RAP is resistant to both pH and heat denaturation. It has been shown to be a potent inhibitor or LRP1 function in both in vitro and in vivo. To stabilise the RAP, the following mutations were made: H257F, H259F, Y260C, H268F, H290F, T297C. LRP1 is an endocytic receptor that interacts with several ligands including alpha 2-macroglobulin. Functionally, the receptor mediates cellular signalling with implications in Alzheimer's disease. This receptor is expressed in brain, liver, and lung and localized to the cytoplasm and nucleus. Expression of LRP1 requires RAP, a molecular chaperone of LRP1.
- Application: Inhibits LRP1 function
- Molecular weight: 38kDa
- Additional notes: This RAP protein was engineered to resist pH and heat-induced denaturation via the addition of a disulfide bond within the D3 domain and elimination of key histidine residues. This stable RAP molecule does not disassociate from LRP1 under acidic conditions and thus functions as a potent LRP1 antagonist both in-vitro and in-vivo.
Handling
- Shipping conditions: Dry Ice
Target Details
- Target: LRP1
- Target alternate names: Lipoprotein receptor-related protein 1
- Target background: LRP1 is an endocytic receptor that interacts with several ligands including alpha 2-macroglobulin. Functionally, the receptor mediates cellular signalling with implications in Alzheimer's disease. This receptor is expressed in brain, liver, and lung and localized to the cytoplasm and nucleus. Expression of LRP1 requires RAP, a molecular chaperone of LRP1.
Application Details
- Application: Inhibits LRP1 function
References
- Prasad et al. 2015. J Biol Chem. 290(28):17262-8. PMID: 26013822.
- Generation of a Potent Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Antagonist by Engineering a Stable Form of the Receptor-associated Protein (RAP) D3 Domain.
